



Arbutus to Report First Quarter 2019 Financial Results

April 29, 2019

WARMINSTER, Pa., April 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 6, 2019. The schedule for the press release and conference call/webcast are as follows:

- Q1 2019 Press Release: May 6, 2019 at 4:00 p.m. ET
- Q1 2019 Conference Call: May 6, 2019 at 4:30 p.m. ET
- Domestic Dial-In Number: (866) 393-1607
- International Dial-In Number: (914) 495-8556
- Conference ID Number: 9448718

A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID 9448718.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information

Investors

Mark Murray
President and CEO
Phone: 604-419-3200
Email: ir@arbutusbio.com

Media

Pam Murphy
Investor Relations Consultant
Phone: 604-419-3200
Email: ir@arbutusbio.com



Source: Arbutus Biopharma Corporation